867 Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.31 |
| 52 Week High | HK$15.86 |
| 52 Week Low | HK$6.27 |
| Beta | 0.83 |
| 11 Month Change | -14.03% |
| 3 Month Change | -17.84% |
| 1 Year Change | -47.06% |
| 33 Year Change | -66.79% |
| 5 Year Change | -17.08% |
| Change since IPO | 109.77% |
Recent News & Updates
Recent updates
An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 20% Undervalued
May 22
China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
May 03We Think Shareholders May Want To Consider A Review Of China Medical System Holdings Limited's (HKG:867) CEO Compensation Package
May 02China Medical System Holdings' (HKG:867) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 19China Medical System Holdings (HKG:867) Is Paying Out Less In Dividends Than Last Year
Mar 29Not Many Are Piling Into China Medical System Holdings Limited (HKG:867) Stock Yet As It Plummets 35%
Mar 28China Medical System Holdings Limited's (HKG:867) Share Price Not Quite Adding Up
Dec 21Is China Medical System Holdings (HKG:867) A Risky Investment?
Dec 04If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Nov 15China Medical System Holdings (HKG:867) Will Pay A Larger Dividend Than Last Year At CN¥0.342
Aug 31China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Aug 30Here's Why We Think China Medical System Holdings (HKG:867) Might Deserve Your Attention Today
Aug 07We Think China Medical System Holdings (HKG:867) Can Manage Its Debt With Ease
May 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 26An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 47% Undervalued
Feb 05China Medical System Holdings (HKG:867) Seems To Use Debt Rather Sparingly
Dec 26If EPS Growth Is Important To You, China Medical System Holdings (HKG:867) Presents An Opportunity
Dec 08Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?
Aug 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued
Jul 08Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
May 16Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Apr 10China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28
Mar 22If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late
Feb 09Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Dec 25Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
Nov 10China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Sep 25China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32
Aug 26Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching
Jul 30An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued
Jun 27China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Jun 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 20Is There An Opportunity With China Medical System Holdings Limited's (HKG:867) 43% Undervaluation?
Mar 25Shareholders Are Loving China Medical System Holdings Limited's (HKG:867) 3.0% Yield
Mar 08Shareholder Returns
| 867 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -4.7% | 1.6% | 0.1% |
| 1Y | -47.1% | -2.8% | 4.6% |
Return vs Industry: 867 underperformed the Hong Kong Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: 867 underperformed the Hong Kong Market which returned 4.6% over the past year.
Price Volatility
| 867 volatility | |
|---|---|
| 867 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 867 has not had significant price volatility in the past 3 months.
Volatility Over Time: 867's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,701 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
| 867 fundamental statistics | |
|---|---|
| Market cap | HK$15.39b |
| Earnings (TTM) | HK$2.58b |
| Revenue (TTM) | HK$8.61b |
6.0x
P/E Ratio1.8x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 867 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.01b |
| Cost of Revenue | CN¥1.94b |
| Gross Profit | CN¥6.08b |
| Other Expenses | CN¥3.68b |
| Earnings | CN¥2.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 75.82% |
| Net Profit Margin | 29.96% |
| Debt/Equity Ratio | 8.3% |
How did 867 perform over the long term?
See historical performance and comparison